Drug Trial Radar · NCT04074590
Study of Efficacy, Safety, and Tolerability of LYS006, in Patients With Mild to Moderate Ulcerative Colitis
Last checked: Nov 19, 2026Latest source record: Jun 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
23
Actual
Start
Feb 3, 2020
Primary completion
Nov 7, 2022
Study completion Nov 7, 2022
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Aug 30, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study was to assess preliminary efficacy, safety, and tolerability of LYS006 in adult patients with mild to moderate ulcerative colitis and to determine if LYS006 has an adequate clinical profile for further development in this indication.
Conditions
- Colitis, Ulcerative
Interventions
LYS006Drug
capsule for oral use
PlaceboDrug
capsule for oral use
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical Remission Rate at the End of the Study TreatmentTime frame: Week 8
Locations
9 sites in 6 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Sofia, Bulgaria
Novartis Investigative Site
Prague, Czech Republic, Czechia
Novartis Investigative Site
Zlín, Czech Republic, Czechia
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Poznan, Poland
Novartis Investigative Site
Nowy Targ, Lesser Poland Voivodeship, Poland
Novartis Investigative Site
Warsaw, Masovian Voivodeship, Poland
Novartis Investigative Site
Novosibirsk, Russia
Novartis Investigative Site
Košice, Slovakia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.